Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.64 USD | +3.47% | +7.19% | -45.51% |
Apr. 11 | Ocuphire Pharma Enrolls 1st Patient in Phase 3 Trial of Visual Acuity Treatment | MT |
Apr. 11 | Ocuphire Pharma, Inc. Announces Global License Agreement with Viatris Inc | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-45.51% | 42M | |
+33.25% | 699B | |
+28.45% | 571B | |
-3.55% | 364B | |
+18.16% | 326B | |
+4.36% | 286B | |
+15.15% | 236B | |
+4.87% | 198B | |
-10.47% | 194B | |
-3.69% | 149B |
- Stock Market
- Equities
- OCUP Stock
- News Ocuphire Pharma, Inc.
- Transcript : Ocuphire Pharma, Inc., Q3 2023 Earnings Call, Dec 05, 2023